ClinicalTrials.gg
Not yet recruitingNCT05558189Updated Nov 25, 2024

Vibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson's Disease Patients

An interventional study of Vibrotactile Coordinated Reset (vCR) in Parkinson Disease, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 35 Years to 92 Years. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
35 Years to 92 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Parkinson Disease by Stanford University — 10 open to participants now, 10 under way, none of them phase 3. Parkinson Disease · Stanford University.

Planned enrollment
16th of 19
10 · median 20
Started
2025
with 5 others
No phase
15 of 19
9 open now
Registered
12th of 19
by date

Among the 19 studies in Parkinson Disease by Stanford University, this one is the 16th largest by planned enrollment, is one of 6 that started in 2025, is one of 15 with no phase, and was the 12th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

10 of the 19 studies in Parkinson Disease by Stanford University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 35 Years to 92 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Parkinson Disease by Stanford University, or all of them as a file.
02

Study summary

The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on refractory post-surgery PD. vCR will be administered with a device called the Stanford Glove. vCR is expected to provide patients with a non-invasive alternative to the most widely used treatments such as levodopa and or deep brain stimulation. Patients will be followed for two years.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
35 Years to 92 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age at the time of enrollment: 35 - 92 years
  2. Diagnosis of idiopathic Parkinson's disease
  3. Surgical treatment for Parkinson's disease that does not involve Deep Brain Stimulation
  4. Fluent in English
  5. Appropriate social support if required during an off state.
  6. Comfortable with technology; can use a computer, check email, and access the internet; can initiate and engage in a virtual meeting for training and monitoring purposes.
  7. Lives in the United States

Exclusion criteria

Exclusion Criteria:

  1. Any significant neuro-psychiatric problems, including acute confusional state, ongoing psychosis, or suicidal tendencies
  2. Any current drug or alcohol abuse.
  3. Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days. Any other trial participation should be approved by the Principal Investigators.
  4. Pregnancy, breast-feeding or wanting to become pregnant
  5. Patient is unable to communicate properly with staff (i.e., severe speech problems)
  6. Excessive drooling
  7. Sensory abnormalities of the fingertips
  8. Deep Brain Stimulation treatment
  9. PD symptoms so severe and that the patient is bed-bound
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Vibrotactile Coordinated Reset (vCR)

    Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain.

    Device: Vibrotactile Coordinated Reset (vCR)

Interventions

  • DeviceVibrotactile Coordinated Reset (vCR)

    The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants who have refractory Parkinson's disease post surgical treatment

06

What researchers measure

Primary outcomes

  1. Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS III) change from baseline to 24 months.

    This scale measures motor ability within Parkinson's patients. For part 3, the scales minimum values is 0 and max value is 132. Higher scores indicate more impaired motor ability, while lower scores indicate less impaired motor ability. A score of 0 indicates no motor impairment.

    Time frame: 24 months

Secondary outcomes

  1. Levodopa equivalent daily dose (LEDD) change from baseline to 24 months

    LEDD is calculated as a daily sum of levodopa in each Parkinson's medication

    Time frame: 24 months

  2. Communicative Participation Item Bank (CPIB; Short Form) change from baseline to 24 months.

    The CPIB is a questionnaire that measures speech complications. The questionnaire is scored from 0 to 30, with a higher score indicating increased speech difficulties.

    Time frame: 24 months

  3. Voice Handicap Index (VHI-10) change from baseline to 24 months

    This questionnaire can be filled out by patients and assesses the impact that voice problems and limitations have on the individual's overall daily function. Questionnaire is scored from 0 to 40, with a higher score indicating increased speech difficulties.

    Time frame: 24 months

  4. Freezing of gait questionnaire (FOG) change from baseline to 24 months

    The Freezing of Gait Questionnaire (FOG) assesses severity unrelated to falls in patients with Parkinson's Disease (PD), FOG frequency, disturbances in gait, and relationship to clinical features conceptually associated with gait and motor aspects (e.g., turning). The FOG is comprised of 6 questions measured on a 0 to 4 scale (where 0 is normal and 4 represents severe abnormalities). The scores are summed together with 0 representing the best possible score and 24 representing the worst possible score.

    Time frame: 24 months

  5. Vibratory temporal discrimination task (VTDT) change from baseline to 24 months.

    The vibratory temporal discrimination task (VTDT) consists of two vibratory bursts, with one burst delivered to the index finger and one burst to the middle finger. This procedure will be performed on the right and left hand separately. The patient is instructed to judge if he/she felt a delay between the two vibratory bursts. The inner stimulus interval (ISI) is RECORDED when the participant indicates that they can feel a difference in time between the two vibrations. The ISI can range from 10ms-110 ms

    Time frame: 24 months

  6. Movement disorders unified Parkinson's rating scale (MDS-UPDRS) part 1 change from baseline to 24 months.

    The MDS-UPDRS part 1 focuses on non-motor symptoms, such as dementia, depression, and psychosis. The total summed score ranges from 0-52 with higher scores indicating increased non-motor impairment.

    Time frame: 24 months

  7. Movement disorders unified Parkinson's rating scale (MDS-UPDRS) part 2 change from baseline to 24 months.

    The MDS-UPDRS part 2 focuses on the patient's ability to perform daily motor activities including dressing, grooming, and using utensils. The total summed score ranges from 0-52 with higher scores indicating increased daily motor impairment.

    Time frame: 24 months

  8. Movement disorders unified Parkinson's rating scale (MDS-UPDRS) part 4 change from baseline to 24 months.

    The MDS-UPDRS 4 focuses on Measures the complications of treatment, e.g. dyskinesias and motor fluctuations. The total summed score ranges from 0-24 with higher scores indicating increased motor complications.

    Time frame: 24 months

  9. Parkinson's disease cognitive functional rating scale (PD-CFRS) change from baseline to 24 months.

    The PD-CFRS capture subjective daily functional cognitive decline among patients with Parkinson's disease over the past 2 weeks. The scale ranges from 0 to 24, with higher scores indicative of cognitive decline.

    Time frame: 24 months

  10. Parkinson's Disease-Cognitive Rating Scale (PDCRS) change from baseline to 24 months.

    The PDCRS is a cognitive test designed to designed to cover the full spectrum of cognitive defects associated with Parkinson's Disease. The total test score ranges from 0 - 134, with higher scores indicating less cognitive impairment.

    Time frame: 24 months

  11. Parkinsons disease quality of life questionnaire-39 (PDQ-39) change from baseline to 24 months

    The PD Quality of Life Questionnaire-39 (PDQ-39) is a self-report questionnaire that examines health related difficulties specific to PD in eight quality of life categories within the last month. Items are grouped into eight scales that are scored by expressing summed item scores as a percentage score ranging between 0 and 100, with higher % indicating more health problems.

    Time frame: 24 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Nov 2026, 15 months later.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 15 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2022
First posted
Sep 28, 2022
StartEst.
Aug 20, 2025
Primary completionEst.
Nov 21, 2026
CompletionEst.
Nov 21, 2026
Last update
Nov 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05558189
Responsible party
Peter Tass, MD, PhD (Protocol Director, Stanford University) — Principal investigator
First posted
Sep 28, 2022
Start date
Aug 20, 2025 (estimated)
Primary completion
Nov 21, 2026 (estimated)
Completion
Nov 21, 2026 (estimated)
Last update
Nov 25, 2024

Study contacts

Jessica K Yankulova
Contact
jessky@stanford.edu
650-474-9547

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion